Please login to the form below
Wilson's disease
This page shows the latest Wilson's disease news and features for those working in and with pharma, biotech and healthcare.
Pfizer buys dwarfism drug company Therachon for $810m
The deal adds to Pfizer’s rare disease portfolio, which just chalked up a major success with the approval of tafamidis products Vyndaqel and Vyndamax for transthyretin amyloid cardiomyopathy (ATTR-CM) ... TA-46 will add to other pipeline candidates
Latest news
-
Alexion adds to pipeline with $1.2bn Syntimmune buy
Alexion used a priority review voucher from an earlier rare disease therapy approval to accelerate the FDA’s deliberations and bring forward a possible approval date. ... $855m, adding orally-active copper binder WTX-101 in phase 3 testing for genetic
-
Alexion adds to pipeline rebuild with $855m Wilson buy
Also acquires the Swedish group’s lead product for Wilson’s disease. Alexion Pharma’s drive to reduce its reliance on cash cow Soliris has gone up a gear with a ... Sweden-based Wilson’s lead product is WTX101, currently in phase III development
More from news
Approximately 1 fully matching, plus 2 partially matching documents found.
Featured jobs
-
Consultant
-
competitive salary
-
Principal Medical Writer
-
£48 - 58, 000 according to skills and experience benefits
- Account Director or Senior Account Director
-
Salary TBC
- Account Director, Medical Communications & Events
-
£50 - 65, 000 according to skills and experience benefits
- Director of Scientific Services, Medical Communications, Six fig...
-
Six figure salary
-
Vice President
-
Competitive Salary Offered
- Account Manager– Medical Communications
-
(Negotiable - depending on experience)
- Senior Medical Writer, MedComms Agency
-
Salary TBC
Subscribe to our email news alerts
- Novartis gets EU approval for multiple sclerosis therapy Mayzent
- Moving annual total (MAT)
- Novartis links up with NHS for speedy access to cholesterol drug inclisiran
- Roche’s SMA treatment risdiplam hits another clinical target
- NICE knocks back AstraZeneca's Tagrisso again
- Lilly will aim for one $1bn-$5bn deal per quarter in 2020
- New coronavirus sees drug developers scramble to develop a vaccine
- Sanofi completes acquisition of immuno-oncology specialist Synthorx
- Roche's checkpoint inhibitor fails pivotal urothelial cancer trial
- Epizyme wins FDA approval for epithelioid sarcoma treatment
- Pharma Brand Planners' Blog (Part 8)
- Happy Chinese New Year 2020 - The Year of The Rat
PMHub
Viseven
Viseven is a full cycle digital agency with 10 years expertise in developing content for the global pharmaceutical market delivering...
Latest intelligence
- Happy Chinese New Year 2020 - The Year of The Rat
- A fond farewell to The Year of the Pig...
- White Paper for download - Explaining the price of your product
- In this white paper, he breaks down the pricing options available to you, shares stories from his extensive experiences, and talks you through how to better define your pricing, step-by-step....
- OPEN Health expands offering with the launch of a new Learning & Development specialist team
- Enhanced expertise to deliver impactful internal training programmes for healthcare clients...
Quick links
Infographics
